دورية أكاديمية
Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab.
| العنوان: | Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab. |
|---|---|
| المؤلفون: | Pistillo MP; IRCCS Ospedale Policlinico San Martino, Tumor Epigenetics Unit, Genova, Italy. Electronic address: mariapia.pistillo@hsanmartino.it., Carosio R; IRCCS Ospedale Policlinico San Martino, Tumor Epigenetics Unit, Genova, Italy., Grillo F; University of Genova, Department of Surgical Sciences and Integrated Diagnostics (DISC), Genova, Italy; IRCCS Ospedale Policlinico San Martino, Anatomic Pathology Unit, Genova, Italy., Fontana V; IRCCS Ospedale Policlinico San Martino, Clinical Epidemiology Unit, Genova, Italy., Mastracci L; University of Genova, Department of Surgical Sciences and Integrated Diagnostics (DISC), Genova, Italy; IRCCS Ospedale Policlinico San Martino, Anatomic Pathology Unit, Genova, Italy., Morabito A; IRCCS Ospedale Policlinico San Martino, Tumor Epigenetics Unit, Genova, Italy., Banelli B; IRCCS Ospedale Policlinico San Martino, Tumor Epigenetics Unit, Genova, Italy., Tanda E; IRCCS Ospedale Policlinico San Martino, Skin Cancer Unit, Genova, Italy., Cecchi F; IRCCS Ospedale Policlinico San Martino, Skin Cancer Unit, Genova, Italy., Dozin B; IRCCS Ospedale Policlinico San Martino, Clinical Epidemiology Unit, Genova, Italy., Gualco M; Ospedale Villa Scassi, ASL3, Anatomic Pathology Unit, Genova, Italy., Salvi S; IRCCS Ospedale Policlinico San Martino, Anatomic Pathology Unit, Genova, Italy., Spagnolo F; IRCCS Ospedale Policlinico San Martino, Skin Cancer Unit, Genova, Italy., Poggi A; IRCCS Ospedale Policlinico San Martino, Molecular Oncology and Angiogenesis Unit, Genova, Italy., Queirolo P; IEO, Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, European Institute of Oncology IRCCS, Milan, Italy. |
| المصدر: | Clinical immunology (Orlando, Fla.) [Clin Immunol] 2020 Jun; Vol. 215, pp. 108428. Date of Electronic Publication: 2020 Apr 25. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Academic Press Country of Publication: United States NLM ID: 100883537 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-7035 (Electronic) Linking ISSN: 15216616 NLM ISO Abbreviation: Clin Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Orlando, FL : Academic Press, c1999- |
| مواضيع طبية MeSH: | Antineoplastic Agents, Immunological/*therapeutic use , CTLA-4 Antigen/*metabolism , Ipilimumab/*therapeutic use , Melanoma/*drug therapy , Melanoma/*metabolism, Adult ; Aged ; Aged, 80 and over ; Biomarkers/metabolism ; Female ; Humans ; Immunotherapy/methods ; Male ; Middle Aged |
| مستخلص: | The expression of the immune checkpoint molecule CTLA-4 has been almost exclusively studied in the T cell lineage, but increasing evidence has shown its expression on tumors with implications for immunotherapy. To date, the degree of expression of CTLA-4 on tumor cells as a predictive biomarker of response to immune checkpoint inhibitors has not been studied. In this report, we analyzed this issue in melanoma patients treated with CTLA-4 inhibitor Ipilimumab (IPI). We show that the level of CTLA-4 expression on melanoma cells is higher than that on tumor infiltrating lymphocytes (TIL) and it is associated with clinical response to IPI therapy supporting the idea of its possible role as a predictive biomarker. Competing Interests: Declaration of Competing Interest Dr. Queirolo served on the Advisory Boards of Roche, Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme, Sanofi and Pierre-Fabre. All other authors have declared no conflict of interest. (Copyright © 2020 Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Best overall response; CTLA-4; Immunohistochemistry; Ipilimumab; Melanoma; TIL |
| المشرفين على المادة: | 0 (Antineoplastic Agents, Immunological) 0 (Biomarkers) 0 (CTLA-4 Antigen) 0 (CTLA4 protein, human) 0 (Ipilimumab) |
| تواريخ الأحداث: | Date Created: 20200429 Date Completed: 20210129 Latest Revision: 20210129 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.clim.2020.108428 |
| PMID: | 32344017 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1521-7035 |
|---|---|
| DOI: | 10.1016/j.clim.2020.108428 |